Minerva Licenses Osmetech's SAM Tech to Study Functional Proteomics | GenomeWeb
NEW YORK (GenomeWeb News) — Minerva Biotechnologies has non-exclusively licensed Osmetech’s self-assembling monolayer technology for use with its proprietary nanoparticle technology, Osmetech said today.
Osmetech said Minerva will use the SAM technology to study signal enhancement, drug design, drug screening, and functional proteomics.
Osmetech exclusively licensed the technology from Harvard University a decade ago. The IP was invented in part by Minerva founder and CSO Cynthia Bamdad.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.